Idioma:

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

Riedl, M. A. ; Aygören‐Pürsün, E. ; Baker, J. ; Farkas, H. ; Anderson, J. ; Bernstein, J. A. ; Bouillet, L. ; Busse, P. ; Manning, M. ; Magerl, M. ; Gompels, M. ; Huissoon, A. P. ; Longhurst, H. ; Lumry, W. ; Ritchie, B. ; Shapiro, R. ; Soteres, D. ; Banerji, A. ; Cancian, M. ; Johnston, D. T. ; Craig, T. J. ; Launay, D. ; Li, H. H. ; Liebhaber, M. ; Nickel, T. ; Offenberger, J. ; Rae, W. ; Schrijvers, R. ; Triggiani, M. ; Wedner, H. J. ; Dobo, S. ; Cornpropst, M. ; Clemons, D. ; Fang, L. ; Collis, P. ; Sheridan, W. P. ; Maurer, M.

Allergy, 2018-09, Vol.73 (9), p.1871-1880 [Periódico revisado por pares]

Denmark: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study
Autor: Riedl, M. A. ; Aygören‐Pürsün, E. ; Baker, J. ; Farkas, H. ; Anderson, J. ; Bernstein, J. A. ; Bouillet, L. ; Busse, P. ; Manning, M. ; Magerl, M. ; Gompels, M. ; Huissoon, A. P. ; Longhurst, H. ; Lumry, W. ; Ritchie, B. ; Shapiro, R. ; Soteres, D. ; Banerji, A. ; Cancian, M. ; Johnston, D. T. ; Craig, T. J. ; Launay, D. ; Li, H. H. ; Liebhaber, M. ; Nickel, T. ; Offenberger, J. ; Rae, W. ; Schrijvers, R. ; Triggiani, M. ; Wedner, H. J. ; Dobo, S. ; Cornpropst, M. ; Clemons, D. ; Fang, L. ; Collis, P. ; Sheridan, W. P. ; Maurer, M.
Assuntos: Administration, Oral ; Adult ; Angioedema ; Angioedemas, Hereditary - diagnosis ; Angioedemas, Hereditary - drug therapy ; Angioedemas, Hereditary - prevention & control ; C1 inhibitor ; Complement component C1 ; Disease Progression ; Edema ; Effectiveness ; Enzyme Inhibitors - administration & dosage ; Enzyme Inhibitors - adverse effects ; Enzyme Inhibitors - pharmacokinetics ; Enzyme Inhibitors - therapeutic use ; Female ; hereditary angioedema ; Humans ; Kallikrein ; Life Sciences ; Male ; Middle Aged ; oral kallikrein inhibitor ; Original ; ORIGINAL ARTICLES ; Plasma kallikrein ; Plasma Kallikrein - antagonists & inhibitors ; Prophylaxis ; Quality of Life ; Randomization ; Recurrence ; Treatment Outcome
É parte de: Allergy, 2018-09, Vol.73 (9), p.1871-1880
Notas: Riedl and Aygören‐Pürsün equally contributed to this article.
Descrição: Background Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo. Methods OPuS‐2 was a Phase 3, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Subjects were administered avoralstat 300 mg, avoralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy endpoint was the angioedema attack rate based on adjudicator‐confirmed attacks. Results A total of 110 subjects were randomized and dosed. The least squares (LS) mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject in each of the avoralstat groups and no subjects in the placebo group were attack‐free during the 84‐day treatment period. The LS mean duration of all confirmed attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life Questionnaire (AE‐QoL), improved QoL was observed for the avoralstat 500 mg group compared with placebo. Avoralstat was generally safe and well tolerated. Conclusions Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1‐INH‐HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo.
Editor: Denmark: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

Denmark: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.